Jenkins S A, Baxter J N, Johnston J N, Devitt P, Shields R
Br J Surg. 1985 Aug;72(8):653-6. doi: 10.1002/bjs.1800720824.
The effects of a selective beta 2-blocker (ICI 118,551) on hepatic haemodynamics were studied in cirrhotic and non-cirrhotic rats. Infusions of 10 and 20 microgram (kg body wt)-1 min-1 beta 2-blocker (in cirrhotic and non-cirrhotic rats) significantly reduced portal pressure, portal venous flow and liver blood flow without altering heart rate. Splanchnic vascular resistance was significantly increased following infusions of 10 and 20 micrograms (kg body wt)-1 min-1 beta 2-blocker. An intraportal injection of beta 2-blocker (10 micrograms body wt)-1 or hepatic artery ligation lowered portal pressure by approximately the same magnitude. Intraportal injection of beta 2-blocker after hepatic artery ligation did not further reduce portal pressure. The results indicate that a selective beta 2-blocker reduces portal pressure by a combination of increased splanchnic vascular resistance and hepatic arterial resistance. It is concluded that a selective beta 2-blocker may be of clinical value in the long-term managements of portal hypertension.
在肝硬化和非肝硬化大鼠中研究了选择性β2受体阻滞剂（ICI 118,551）对肝脏血流动力学的影响。以10和20微克/（千克体重）-1·分钟-1的剂量输注β2受体阻滞剂（在肝硬化和非肝硬化大鼠中）可显著降低门静脉压力、门静脉血流量和肝脏血流量，而不改变心率。输注10和20微克/（千克体重）-1·分钟-1的β2受体阻滞剂后，内脏血管阻力显著增加。门静脉内注射β2受体阻滞剂（10微克/体重）-1或肝动脉结扎可使门静脉压力降低大致相同的幅度。肝动脉结扎后门静脉内注射β2受体阻滞剂并未进一步降低门静脉压力。结果表明，选择性β2受体阻滞剂通过增加内脏血管阻力和肝动脉阻力的联合作用来降低门静脉压力。结论是，选择性β2受体阻滞剂在门静脉高压的长期管理中可能具有临床价值。
